阿维A治疗儿童脓疱型银屑病的疗效及安全性观察

Investigation of efficacy and safety on acitretin monotherapy for juvenile generalized pustule psoriasis

目的:对阿维A治疗儿童脓疱型银屑病的疗效及安全性进行观察、评估。方法:对10例儿童泛发性脓疱型银屑病进行回顾性研究,起始剂量使用0.6~1.0 mg/(kg·d)阿维A持续治疗4~6周,过渡期减量为0.2~0.4 mg/(kg·d)治疗4~6周,维持剂量为0.2~0.3 mg/(kg·d),持续6~12周,随访7~32个月,观察患者疗效及不良反应。结果:9例儿童脓疱型银屑病PASI评分下降率均≥90%,1例为60%~<90%。最常见的不良反应有皮肤干燥(60%,6/10)、瘙痒(40%,4/10)、唇炎(10%,1/10),其他副作用如骨骼发育迟缓、肝功能异常等均未发现。结论:低剂量使用阿维A治疗儿童脓疱型银屑病安全且疗效佳。

Objective：To observe and evaluate the efficacy and safety of acitretin treatment in juvenile pustular psoriasis （PP）. Methods： A retrospective study was undertaken for 10 children with PP, who received acitretin in the starting dose of 0. 6-1.0mg/（ kg·d） for 4-6 weeks, the transition dose in 0. 2 -0. 4 mg/（kg·d） for 4-6 weeks, and the maintenance dose of 0. 2 0. 3 mg/（kg·d） for 6 -12 weeks. The curative effect and adverse reaction of patients were detec- ted at follow-up period ranged from 7 to 32 months. No other side effects were found such as abnor-mality in bone growth and liver function tests. Results ： The PASI score decreasing rate is over 90% in 9 cases, and one is 60%- 〈 90%. The common side effects in acitretin treatment with PP were dry skin （60% ,6/10）, cheilitis （40% ,4/10）, itching （10% ,1/10）. Conclusion： Low dose of acitrerin monotherapy for children cases with PP were with satisfactory efficacy and safety overall.